In addition to antitumor effects through suppressing cell proliferation and angiogenesis, we found that combined treatment with PS-MYC and PS-Gp130 peptides remarkably decreased the expression level of programmed cell death ligand 1 (PD-L1) in mouse PDAC tumors (Figure 9D) while activating tumor-infiltrating CD8+ T cells, as shown by IFN-γ production (Figure 9E). The gene discussed is CD8A; the disease is neoplasm.